2016 Hematological Malignancies

Points for discussion

• Bx was not done: course of disease (PET-2, PET-4, PET-6) + increase in size. • Aim was to get CMR (-ve PET) prior to ASCT. • Expected salvage chemo alone is not adequate: – Bulky disease – Primary refractory – CORAL data re poor salvage-ability >R • response rate 51% v 83% • 3y EFS of 21% v 47% • Primary refractory disease worse • Retrospective evidence of benefit of peri-transplant RT , particularly after R • Concern about pneumonitis ?